Zepbound tops Wegovy for weight loss in Eli Lilly study
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...
Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy
Eli Lilly & Co. Inc.’s stock LLY rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...
Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
Zepbound bests Wegovy for weight loss in new trial
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.
Becker's Hospital Review56m
Zepbound outperforms Wegovy for weight loss: Study
A new phase 3 clinical trial found that Eli Lilly's weight loss drug Zepbound resulted in significantly greater weight loss than Wegovy. Over a 72-week period, patients taking Zepbound lost an average ...
BioPharma Dive17m
Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...